Charles River Laboratories International Inc
CRL143.280USD
-7.750-5.13%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
7.04BMarktkapitalisierung
683.42KGV TTM
mehr Informationen über Charles River Laboratories International Inc Unternehmen
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Unternehmensinformationen
BörsenkürzelCRL
Name des UnternehmensCharles River Laboratories International Inc
IPO-datumJun 23, 2000
Gegründet am1994
CEOMr James C. Foster
Anzahl der mitarbeiter18600
WertpapierartOrdinary Share
GeschäftsjahresendeJun 23
Addresse251 Ballardvale St
StadtWILMINGTON
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl01887
Telefon17812226000
Websitehttps://www.criver.com/
BörsenkürzelCRL
IPO-datumJun 23, 2000
Gegründet am1994
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr James C. Foster
Mr James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
13.68K
-2.74%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+31.35%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+155.42%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+64.49%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr James C. Foster
Mr James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
13.68K
-2.74%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Apr 6
Währung: USDAktualisiert: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
DSA
2.45B
60.53%
RMS
829.38M
20.48%
Manufacturing
769.33M
19.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.24B
55.31%
Europe
1.08B
26.62%
Canada
482.09M
11.90%
Asia Pacific (Region)
196.95M
4.86%
Other
52.82M
1.30%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
DSA
2.45B
60.53%
RMS
829.38M
20.48%
Manufacturing
769.33M
19.00%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.41%
Wellington Management Company, LLP
8.72%
BlackRock Institutional Trust Company, N.A.
5.92%
UBS Financial Services, Inc.
4.86%
Kayne Anderson Rudnick Investment Management, LLC
3.97%
Other
64.11%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.41%
Wellington Management Company, LLP
8.72%
BlackRock Institutional Trust Company, N.A.
5.92%
UBS Financial Services, Inc.
4.86%
Kayne Anderson Rudnick Investment Management, LLC
3.97%
Other
64.11%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
51.53%
Investment Advisor
39.65%
Hedge Fund
7.75%
Research Firm
7.70%
Pension Fund
1.84%
Bank and Trust
1.53%
Sovereign Wealth Fund
1.10%
Individual Investor
1.05%
Insurance Company
0.08%
Institutionelle Beteiligung
Aktualisiert: Mon, Jan 20
Aktualisiert: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1407
54.59M
111.11%
-3.65M
2024Q4
1423
54.85M
107.26%
-4.35M
2024Q3
1392
53.78M
105.14%
-5.12M
2024Q2
1399
54.00M
104.84%
-4.00M
2024Q1
1393
53.76M
104.37%
-4.04M
2023Q4
1424
53.56M
104.42%
-4.24M
2023Q3
1446
53.56M
104.42%
-3.98M
2023Q2
1427
52.88M
103.32%
-3.95M
2023Q1
1431
52.72M
103.01%
-2.79M
2022Q4
1416
51.28M
100.65%
-3.46M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
6.13M
12.49%
+58.13K
+0.96%
Dec 31, 2024
Wellington Management Company, LLP
4.08M
8.3%
+335.66K
+8.97%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
2.95M
6.01%
-51.78K
-1.72%
Dec 31, 2024
Kayne Anderson Rudnick Investment Management, LLC
1.81M
3.68%
-134.28K
-6.92%
Dec 31, 2024
State Street Global Advisors (US)
2.18M
4.44%
+51.15K
+2.40%
Dec 31, 2024
Allspring Global Investments, LLC
1.81M
3.68%
+47.22K
+2.68%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.23M
2.51%
+14.79K
+1.21%
Dec 31, 2024
Impactive Capital LP
1.20M
2.45%
+825.95K
+219.44%
Dec 31, 2024
Ariel Investments, LLC
1.07M
2.17%
+169.64K
+18.90%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
First Trust NASDAQ Pharmaceuticals ETF
1.63%
ROBO Global Healthcare Technology & Innovation ETF
1.41%
VanEck Biotech ETF
1.41%
Schwab Ariel ESG ETF
1.35%
Invesco S&P 500 Equal Weight Health Care ETF
1.34%
Franklin Genomic Advancements ETF
1.25%
Invesco S&P 500 High Beta ETF
0.9%
Principal Quality ETF
0.78%
iShares Health Innovation Active ETF
0.7%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.68%
Mehr Anzeigen
First Trust NASDAQ Pharmaceuticals ETF
Anteil1.63%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.41%
VanEck Biotech ETF
Anteil1.41%
Schwab Ariel ESG ETF
Anteil1.35%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.34%
Franklin Genomic Advancements ETF
Anteil1.25%
Invesco S&P 500 High Beta ETF
Anteil0.9%
Principal Quality ETF
Anteil0.78%
iShares Health Innovation Active ETF
Anteil0.7%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
Anteil0.68%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
